Johnson & Johnson (NYSE: JNJ) remains one of the most dependable dividend growth stocks in the healthcare sector, having raised its payout for 62 consecutive years. The company’s recent separation of its consumer health business into Kenvue has sharpened its focus on pharmaceuticals and medical devices, creating a more streamlined operation for long-term shareholders.
The setup
JNJ is the largest healthcare conglomerate in the United States by market capitalization. After spinning off Kenvue in 2023, the company narrowed its portfolio to two segments: Innovative Medicine and MedTech. This structure allows management to allocate capital toward high-margin drug development and advanced surgical technologies.
The dividend history is among the best in the S&P 500. Sixty-two years of consecutive increases places JNJ in the elite Dividend King category, a distinction reserved for companies with 50 or more years of uninterrupted payout growth. Only a handful of public companies have achieved this milestone.
Key numbers
| Metric | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck (MRK) |
|---|---|---|---|
| Current Dividend Yield | 2.85% | 3.45% | 3.20% |
| Consecutive Years of Increases | 62 | 12 | 13 |
| Payout Ratio | 48% | 52% | 46% |
| Forward P/E Ratio | 16.8x | 17.2x | 13.5x |
| Market Cap | $378B | $312B | $285B |
Per $100,000 invested: annual income comparison
| Stock | Shares per $100K | Annual Dividend Income |
|---|---|---|
| Johnson & Johnson (JNJ) | 724 | $2,850 |
| AbbVie (ABBV) | 712 | $3,450 |
| Merck (MRK) | 798 | $3,200 |
What to watch
The pharmaceutical pipeline is the primary growth driver. JNJ’s oncology franchise, led by Darzalex and Erleada, continues to deliver double-digit revenue growth. The immunology portfolio, including Stelara and Tremfya, faces biosimilar competition but retains significant market share.
Investors should pay attention to talc litigation headwinds. The company has set aside billions for settlement costs related to baby powder lawsuits, and ongoing cases create uncertainty around cash flow allocation. Any adverse ruling could pressure the share price and raise questions about the dividend trajectory.
Analysts at Goldman Sachs maintain a “Buy” rating on JNJ with a price target of $178. They highlight the company’s diversified revenue base and strong free cash flow generation as reasons for confidence. Stephens assigns a price target of $175, noting that the pharmaceutical pipeline offsets near-term litigation uncertainty.
Common mistakes income investors make with pharma stocks
Some investors underestimate patent cliff risk. When blockbuster drugs lose exclusivity, revenue can decline sharply within 12 to 24 months. JNJ’s broad pipeline helps mitigate this risk, but no pharmaceutical company is immune to generic competition.
Others ignore litigation exposure. Healthcare companies face constant legal challenges, and settlement costs can divert cash that might otherwise fund dividend increases or share buybacks. Monitoring quarterly disclosures for litigation reserves is essential for dividend-focused investors.
Bottom line
Johnson & Johnson offers income investors a 2.85 percent yield backed by six decades of uninterrupted dividend growth. The post-Kenvue structure simplifies the story, and the pharmaceutical pipeline provides a credible path to modest earnings expansion.
For conservative portfolios seeking healthcare exposure with a reliable income stream, JNJ remains a foundational holding. The yield is competitive within the sector, and the payout ratio leaves room for future increases even if earnings growth slows.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week.
Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
